2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Apeptico Forschung und Entwicklung GmbH is a company with 2 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| high altitude pulmonary edema | synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys | Des.TrialAppr. |
| primary biliary cholangitis | solnatide | Des.TrialAppr. |
| primary cutaneous lymphoma | solnatide | Des.TrialAppr. |
| primary hyperoxaluria | solnatide | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
11
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio